NEW YORK (GenomeWeb News) – Illumina today said that its board of directors has authorized the repurchase of up to $100 million of the firm's outstanding common stock.

Illumina said that the shares may be purchased either on the open market or under a 10b5-1 trading program, which enables the company to purchase its shares at times when it otherwise might be prevented from doing so under insider trading laws or self-imposed trading blackout periods. The firm said that purchases will be funded through its existing cash balances.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.